AUTAC1 is a MetAP2-targeting autophagy-mediated degrader (AUTAC). AUTACs contain a degradation tag and a warhead to provide target specificity. AUTAC1 contains an FBnG (p-Fluorobenzyl Guanine) and a Fumagillol moiety. Fumagillol binds covalently to MetAP2[1].
体外研究 (In Vitro)
AUTAC1 (1-100 μM, 24 h) silences endogenous MetAP2 in hela cells[1].
Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis[1]
Cell Line:
HeLa cells.
Concentration:
1-100 μM.
Incubation Time:
24 h.
Result:
Silenced endogenous MetAP2.
分子量
931.08
Formula
C44H63FN8O11S
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Daiki Takahashi, et al. AUTACs: Cargo-Specific Degraders Using Selective Autophagy. Mol Cell. 2019 Dec 5;76(5):797-810.e10.
M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 54 nM and a Ki of 4.33 nM. M8891 does not inhibit MetAP-1 (IC50>10 µM)[1]. M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral activity[2].
IC50 & Target
IC50: 54 nM (MetAP-2)[1] Ki: 4.33 nM (MetAP-2)[1]
体外研究 (In Vitro)
M8891 has an IC50 of 20 nM for HUVEC proliferation[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究 (In Vivo)
M8891 (po; 20 mg/kg; once a day for 14 days) exhibits strong tumor growth inhibition[1]. M8891 (iv; 0.2 mg/kg) shows low clearance (CL ~0.03-0.4 L/h/kg corresponding to ~1-6% of the liver blood-flow), small to medium volume of distribution (Vss ~0.23-1.3 L/kg), and medium to high oral bioavailability (F ~40-80%)[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Female CD-1 nude mice aged 6-7 weeks with human U87-MG glioblastoma[1]
Dosage:
20 mg/kg
Administration:
Po; once a day for 14 days
Result:
Exhibited strong tumor growth inhibition.
Animal Model:
Rat, dog and monkey[1]
Dosage:
0.2 mg/kg (Pharmacokinetic Analysis)
Administration:
IV
Result:
Showed low clearance (CL ~0.03-0.4 L/h/kg corresponding to ~1-6% of the liver blood-flow), small to medium volume of distribution (Vss ~0.23-1.3 L/kg), and medium to high oral bioavailability (F ~40-80%).
Clinical Trial
分子量
385.36
Formula
C20H17F2N3O3
CAS 号
1464842-09-8
运输条件
Room temperature in continental US; may vary elsewhere.
[1]. Heinrich T, et al. Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor M8891: A Clinical Compound for the Treatment of Cancer. J Med Chem. 2019 Dec 26;62(24):11119-11134.
[2]. Manja Friese-Hamim, et al. Abstract 3075: Antitumor activity of M8891, a potent and reversible inhibitor of methionine aminopeptidase 2.